• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    2/13/23 4:23:59 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADOC alert in real time by email
    SC 13G/A 1 d438983dsc13ga.htm SCHEDULE 13G/A Schedule 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Edoc Acquisition Corp

    (Name of Issuer)

    Class A Ordinary Shares, $.0001 par value per share

    (Title of Class of Securities)

    G4000A102

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

    CUSIP No.    G4000A102

     

      1    

      Names of Reporting Persons

     

      Periscope Capital Inc.

      2  

      Check the appropriate box if a member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

       6  

      Shared Voting Power

     

      0

       7  

      Sole Dispositive Power

     

       8  

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.00%

    12  

      Type of Reporting Person (See Instructions)

     

      FI

     

    Page 2 of 5


    Item 1.

     

    (a)

    Name of Issuer:

    Edoc Acquisition Corp

     

    (b)

    Address of Issuer’s Principal Executive Offices:

    7612 Main Street Fishers, Suite 200, Victor, NY 14564

    Item 2.

     

    (a)

    Name of Person Filing:

    This Schedule 13G is being filed on behalf of Periscope Capital Inc. (“Periscope”) with respect to the shares of Class A Ordinary Shares, $.0001 par value per share (the “Ordinary Shares”), of Edoc Acquisition Corp, a Cayman Islands exempted company (the “Issuer”).

    Periscope, which is the beneficial owner of 0 shares of Ordinary Shares, acts as investment manager of, and exercises investment discretion with respect to, certain private investment funds (each, a “Periscope Fund”) that collectively directly own 0 shares of Ordinary Shares.

    The filing of this statement should not be construed as an admission that Periscope is, for the purpose of Section 13 of the Act, the beneficial owner of the Ordinary Shares owned by the Periscope Funds.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    333 Bay Street, Suite 1240, Toronto, Ontario, Canada M5H 2R2

     

    (c)

    Citizenship:

    See Row 4 of the Cover Page.

     

    (d)

    Title and Class of Securities:

    Class A Ordinary Shares, $.0001 par value per share

     

    (e)

    CUSIP No.:

    G4000A102

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☒    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

     

    Page 3 of 5


    If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Non-U.S. investment adviser.

     

    Item 4.

    Ownership

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the Cover Page and is incorporated herein by reference.

    Periscope expressly declares that this filing shall not be construed as an admission that it is, for the purposes of Sections 13(d) or 13(g) of the Act, the beneficial owner of the securities owned by the Periscope Funds.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 4 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2023

    PERISCOPE CAPITAL INC.

     

    By: /s/ Lisa Shostack                        
    Lisa Shostack, General Counsel

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    Page 5 of 5

    Get the next $ADOC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADOC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Yakira Capital Management, Inc. disposed of $2,662,742 worth of Class A Ordinary Shares (248,622 units at $10.71)

    4 - Edoc Acquisition Corp. (0001824884) (Issuer)

    2/23/23 5:01:04 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Yakira Capital Management, Inc. claimed ownership of 275,000 units of Class A Ordinary Shares

    3 - Edoc Acquisition Corp. (0001824884) (Issuer)

    1/26/23 2:36:23 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Li Yan Michael

    3 - Edoc Acquisition Corp. (0001824884) (Issuer)

    11/7/22 5:20:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edoc Acquisition Corp. Announces Postponement of Special Meeting of Shareholders on Proposed Business Combination

    Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (NASDAQ:ADOC) ("EDOC") announced today that it has postponed its extraordinary general meeting of its shareholders (the "Meeting") to approve its proposed initial business combination, which was re-scheduled from February 26, 2024 to February 28, 2024, has been further postponed to 4:30p.m. Eastern Time, on Tuesday, March 5, 2024. At the Meeting, shareholders of EDOC will be asked to vote on proposals to approve, among other things, its proposed initial business combination with Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Pubco"), pursuant to a Business Combination Agreement by and among EDOC

    2/27/24 5:32:10 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Edoc Acquisition Corp. Announces Postponement of Special Meeting of Stockholders on Proposed Business Combination

    Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) --  EDOC Acquisition Corp. (NASDAQ:ADOC) ("EDOC") announced today that it has postponed its extraordinary general meeting of its shareholders (the "Meeting") to approve its proposed initial business combination, which was scheduled for February 26, 2024, has been postponed to 10:00 a.m. Eastern Time, on Wednesday, February 28, 2024. At the Meeting, shareholders of EDOC will be asked to vote on proposals to approve, among other things, its proposed initial business combination with Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Pubco"), pursuant to a Business Combination Agreement by and among EDOC, American Physicians LL

    2/23/24 5:45:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Australian Oilseeds and EDOC Acquisition Corp. Announce Effectiveness of Registration Statement and Date of Shareholder Meeting to Approve Proposed Business Combination

    ~ Shareholder Meeting of EDOC Acquisition Corp. to Approve Business CombinationScheduled for February 26, 2024 ~ ~ EDOC Shareholders of Record as of February 2, 2024, are Eligible to Vote at Meeting ~ ~ Upon Closing, Australian Oilseeds Investments Pty Ltd. is Expected to Trade on Nasdaq Under the Ticker "COOT" ~ Victor, NY and Cootamundra New South Wales, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Australian Oilseeds" or "Pubco") and EDOC Acquisition Corp., a publicly-traded special purpose acquisition company ("EDOC") (NASDAQ:ADOC, ADOCW, ADOCR))), today announced that the Securities and Exchange Commission ("SEC")

    2/7/24 3:00:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    2/14/24 12:48:37 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    2/13/24 4:41:59 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    1/31/24 6:08:55 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    SEC Filings

    View All

    SEC Form 15-12G filed by Edoc Acquisition Corp.

    15-12G - Edoc Acquisition Corp. (0001824884) (Filer)

    4/1/24 6:02:12 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Edoc Acquisition Corp. (0001824884) (Filer)

    3/28/24 5:16:10 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 25-NSE filed by Edoc Acquisition Corp.

    25-NSE - Edoc Acquisition Corp. (0001824884) (Subject)

    3/22/24 8:52:21 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care